Clinical Trials Browser

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04831450 2022-08-04

Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04763616 2021-09-24

ICING

Phase 2 Recruiting

37 enrolled

Lymphoid

Natural Killer/T-cell Lymphoma

Clinical Trials

I-SPY

RAD-IO

CEMI-first

TOP 2301: Neoadjuvant Chemo for NSCLC

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

MINIMA

LAG-BOOST

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

GAP Cemi

N-PLANC

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

CECYDE

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

SPORADIC

LAG-MAPS

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

META-1

NACho

NeoMatryx

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

SWITCH

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

HYPERBOLIC

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

PALACE

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

INTERVAL

TRIPL

NeoSTOP-IT

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

BRAVA PENILE

BRAVA VULVAR

IMMUNOLIFE2

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

DISCERN

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

ICING